Literature DB >> 31884793

Quantitative Proteome Responses to Oncolytic Reovirus in GM-CSF- and M-CSF-Differentiated Bone Marrow-Derived Cells.

Michael A Giacomantonio1, Andra M Sterea2, Youra Kim1, Joao A Paulo3, Derek R Clements1, Barry E Kennedy1, Moamen J Bydoun1, Ge Shi1, David M Waisman1,4, Steven P Gygi3, Carman A Giacomantonio1,5, J Patrick Murphy1,6, Shashi Gujar1,2,7,8.   

Abstract

The efficacy of oncolytic viruses (OVs), such as reovirus, is dictated by host immune responses, including those mediated by the pro- versus anti-inflammatory macrophages. As such, a detailed understanding of the interaction between reovirus and different macrophage types is critical for therapeutic efficacy. To explore reovirus-macrophage interactions, we performed tandem mass tag (TMT)-based quantitative temporal proteomics on mouse bone marrow-derived macrophages (BMMs) generated with two cytokines, macrophage colony stimulating factor (M-CSF) and granulocytic-macrophage colony stimulating factor (GM-CSF), representing anti- and proinflammatory macrophages, respectively. We quantified 6863 proteins across five time points in duplicate, comparing M-CSF (M-BMM) and GM-CSF (GM-BMM) in response to OV. We find that GM-BMMs have lower expression of key intrinsic proteins that facilitate an antiviral immune response, express higher levels of reovirus receptor protein JAM-A, and are more susceptible to oncolytic reovirus infection compared to M-BMMs. Interestingly, although M-BMMs are less susceptible to reovirus infection and subsequent cell death, they initiate an antireovirus adaptive T cell immune response comparable to that of GM-BMMs. Taken together, these data describe distinct proteome differences between these two macrophage populations in terms of their ability to mount antiviral immune responses.

Entities:  

Keywords:  antigen presentation/processing; antiviral immune response; cell differentiation; macrophages; oncolytic viruses; quantitative proteomics; reovirus; viral defense

Mesh:

Substances:

Year:  2020        PMID: 31884793      PMCID: PMC7294930          DOI: 10.1021/acs.jproteome.9b00583

Source DB:  PubMed          Journal:  J Proteome Res        ISSN: 1535-3893            Impact factor:   4.466


  62 in total

1.  Activity levels of cathepsins B and L in tumor cells are a biomarker for efficacy of reovirus-mediated tumor cell killing.

Authors:  Y Terasawa; T Hotani; Y Katayama; M Tachibana; H Mizuguchi; F Sakurai
Journal:  Cancer Gene Ther       Date:  2015-01-30       Impact factor: 5.987

2.  Tumor location determines tissue-specific recruitment of tumor-associated macrophages and antibody-dependent immunotherapy response.

Authors:  Birgit Lehmann; Markus Biburger; Christin Brückner; Andrea Ipsen-Escobedo; Sina Gordan; Christian Lehmann; David Voehringer; Thomas Winkler; Niels Schaft; Diana Dudziak; Horia Sirbu; Georg F Weber; Falk Nimmerjahn
Journal:  Sci Immunol       Date:  2017-01-06

3.  Intravenous delivery of oncolytic reovirus to brain tumor patients immunologically primes for subsequent checkpoint blockade.

Authors:  Adel Samson; Karen J Scott; David Taggart; Emma J West; Erica Wilson; Gerard J Nuovo; Simon Thomson; Robert Corns; Ryan K Mathew; Martin J Fuller; Timothy J Kottke; Jill M Thompson; Elizabeth J Ilett; Julia V Cockle; Philip van Hille; Gnanamurthy Sivakumar; Euan S Polson; Samantha J Turnbull; Elizabeth S Appleton; Gemma Migneco; Ailsa S Rose; Matthew C Coffey; Deborah A Beirne; Fiona J Collinson; Christy Ralph; D Alan Anthoney; Christopher J Twelves; Andrew J Furness; Sergio A Quezada; Heiko Wurdak; Fiona Errington-Mais; Hardev Pandha; Kevin J Harrington; Peter J Selby; Richard G Vile; Stephen D Griffin; Lucy F Stead; Susan C Short; Alan A Melcher
Journal:  Sci Transl Med       Date:  2018-01-03       Impact factor: 17.956

4.  Tumor-associated macrophages and survival in classic Hodgkin's lymphoma.

Authors:  Christian Steidl; Tang Lee; Sohrab P Shah; Pedro Farinha; Guangming Han; Tarun Nayar; Allen Delaney; Steven J Jones; Javeed Iqbal; Dennis D Weisenburger; Martin A Bast; Andreas Rosenwald; Hans-Konrad Muller-Hermelink; Lisa M Rimsza; Elias Campo; Jan Delabie; Rita M Braziel; James R Cook; Ray R Tubbs; Elaine S Jaffe; Georg Lenz; Joseph M Connors; Louis M Staudt; Wing C Chan; Randy D Gascoyne
Journal:  N Engl J Med       Date:  2010-03-11       Impact factor: 91.245

5.  Proteomic Analysis Reveals Distinct Metabolic Differences Between Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) and Macrophage Colony Stimulating Factor (M-CSF) Grown Macrophages Derived from Murine Bone Marrow Cells.

Authors:  Yi Rang Na; Ji Hye Hong; Min Yong Lee; Jae Hun Jung; Daun Jung; Young Won Kim; Dain Son; Murim Choi; Kwang Pyo Kim; Seung Hyeok Seok
Journal:  Mol Cell Proteomics       Date:  2015-07-30       Impact factor: 5.911

6.  Structure-function analysis of reovirus binding to junctional adhesion molecule 1. Implications for the mechanism of reovirus attachment.

Authors:  J Craig Forrest; Jacquelyn A Campbell; Pierre Schelling; Thilo Stehle; Terence S Dermody
Journal:  J Biol Chem       Date:  2003-09-09       Impact factor: 5.157

7.  Interferon-inducible transmembrane protein 3 (IFITM3) restricts reovirus cell entry.

Authors:  Amanda A Anafu; Christopher H Bowen; Christopher R Chin; Abraham L Brass; Geoffrey H Holm
Journal:  J Biol Chem       Date:  2013-05-06       Impact factor: 5.157

8.  Stabilin-1 expression defines a subset of macrophages that mediate tissue homeostasis and prevent fibrosis in chronic liver injury.

Authors:  Pia Rantakari; Daniel A Patten; Joona Valtonen; Marika Karikoski; Heidi Gerke; Harriet Dawes; Juha Laurila; Steffen Ohlmeier; Kati Elima; Stefan G Hübscher; Chris J Weston; Sirpa Jalkanen; David H Adams; Marko Salmi; Shishir Shetty
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-29       Impact factor: 11.205

Review 9.  Antigen-Presenting Cells and Antigen Presentation in Tertiary Lymphoid Organs.

Authors:  Catherine E Hughes; Robert A Benson; Marija Bedaj; Pasquale Maffia
Journal:  Front Immunol       Date:  2016-11-07       Impact factor: 7.561

Review 10.  Reovirus in cancer therapy: an evidence-based review.

Authors:  Derek Clements; Erin Helson; Shashi A Gujar; Patrick Wk Lee
Journal:  Oncolytic Virother       Date:  2014-07-09
View more
  1 in total

Review 1.  Role of Myeloid Cells in Oncolytic Reovirus-Based Cancer Therapy.

Authors:  Vishnupriyan Kumar; Michael A Giacomantonio; Shashi Gujar
Journal:  Viruses       Date:  2021-04-10       Impact factor: 5.048

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.